Cover Image
Read Now

CADTH Canadian drug expert committee recommendation: Cysteamine ophthalmic solution (Cystadrops -- recordati rare diseases Canada Inc.) indication : treatment of corneal cystine crystal deposits (CCCDs) in adults and children from 2 years of age with cystinosis

The CADTH Canadian Drug Expert Committee (CDEC) recommends that cysteamine hydrochloride (CH) 0.55% ophthalmic solution be reimbursed for the treatment of CCCDs in adults and children from two years of age with cystinosis only if the following conditions are met: Patient has a diagnosis of cystinosi...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health June 2019, 2019
Edition:Version: Final
Series:CADTH common drug review
Subjects:
Insurance, Health, Reimbursement
Canada
Cysteamine / Therapeutic Use
Cystinosis / Complications
Cost-benefit Analysis
Corneal Diseases / Drug Therapy
Corneal Diseases / Etiology
Ophthalmic Solutions / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02092nam a2200361 u 4500
001 EB001892079
003 EBX01000000000000001055226
005 00000000000000.0
007 tu|||||||||||||||||||||
008 200301 r ||| eng
245 0 0 |a CADTH Canadian drug expert committee recommendation: Cysteamine ophthalmic solution (Cystadrops -- recordati rare diseases Canada Inc.)  |h Elektronische Ressource  |b indication : treatment of corneal cystine crystal deposits (CCCDs) in adults and children from 2 years of age with cystinosis 
246 3 1 |a Cysteamine ophthalmic solution (Cystadrops -- recordati rare diseases Canada Inc.) 
246 3 1 |a Drug reimbursement recommendation Cysteamine (Cystadrops) 
250 |a Version: Final 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c June 2019, 2019 
300 |a 1 PDF file (8 pages) 
653 |a Insurance, Health, Reimbursement 
653 |a Canada 
653 |a Cysteamine / therapeutic use 
653 |a Cystinosis / complications 
653 |a Cost-Benefit Analysis 
653 |a Corneal Diseases / drug therapy 
653 |a Corneal Diseases / etiology 
653 |a Ophthalmic Solutions / therapeutic use 
710 2 |a CADTH Canadian Drug Expert Committee 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH common drug review 
500 |a "Final." 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK546258  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a The CADTH Canadian Drug Expert Committee (CDEC) recommends that cysteamine hydrochloride (CH) 0.55% ophthalmic solution be reimbursed for the treatment of CCCDs in adults and children from two years of age with cystinosis only if the following conditions are met: Patient has a diagnosis of cystinosis and evidence of CCCDs; Patient must be under the care of an ophthalmologist experienced in the management of the ocular manifestations of cystinosis; Reduction in price 

Similar Items